Lifelong Genetic Inhibition of PCSK9 and Hepatic Safety

This genetic association study investigates whether the full spectrum of rare PCSK9 loss-of-function variants is associated with incident liver-related outcomes, given the development of therapies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9).

Corresponding Authors: Alessia Di Costanzo, PhD, (alessia.dicostanzo@uniroma1.it), and Marcello Arca, MD, Department of Translational and Precision Medicine, Sapienza University of Rome, Viale del Policlinico, 155 Rome, Lazio, IT 00185 (marcello.arca@uniroma1.it).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.